MAYO CLINIC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1889-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mayoclinic.org
Remote Monitoring with Health-Coaching for Lifestyle Changes in Patients with Lung Cancer Related Fatigue
Not Applicable
Terminated
- Conditions
- Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC V8Stage IIIA Lung Cancer AJCC V8Stage IIIB Lung Cancer AJCC V8Stage IIIC Lung Cancer AJCC V8Stage IV Lung Cancer AJCC V8Stage IVA Lung Cancer AJCC V8Stage IVB Lung Cancer AJCC V8
- Interventions
- Other: Exercise CounselingOther: Exercise InterventionOther: Internet-Based InterventionOther: InterviewOther: Medical Device Usage and EvaluationOther: Questionnaire Administration
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 7
- Registration Number
- NCT05407038
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome
- Conditions
- Bariatric Surgery CandidateHealthyObese
- Interventions
- Procedure: Endoscopic biopsy
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 52
- Registration Number
- NCT05408728
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
Targeting Inflammation for Endometrial Cancer Prevention
Active, not recruiting
- Conditions
- Endometrial Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 191
- Registration Number
- NCT05407025
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Phase 3
Withdrawn
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmAdvanced Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT05403580
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 700
- Registration Number
- NCT05399277
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
Active, not recruiting
- Conditions
- Bladder Carcinoma
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT05399004
Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe
Not Applicable
Completed
- Conditions
- Lung Diseases, ObstructiveLesions MassBronchi--Diseases
- Interventions
- Device: Cryoprobe biopsyProcedure: Forceps biopsy
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT05399082
- Locations
- 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
In-person Focus Groups in the Management of Urinary Incontinence in Women
Completed
- Conditions
- Urinary Incontinence
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 10
- Registration Number
- NCT05395793
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Phase 1
Recruiting
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 49
- Registration Number
- NCT05392946
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, the Sofusa-2 Study
Phase 1
Active, not recruiting
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC V8MelanomaMetastatic MelanomaRecurrent Metastatic Melanoma
- Interventions
- Biological: Anti-PD-L1 Monoclonal Antibody IMC-001Procedure: Punch Biopsy
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 3
- Registration Number
- NCT05393713
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath